Takeda logo

Cancer Therapies Pipeline | Takeda Oncology

Our Pipeline

Our Pipeline

Our research and development efforts focus on advancing medicines for thoracic, gastrointestinal and hematologic cancers by leveraging modalities best suited to make a difference in the treatment of these diseases. Our core modalities include antibody drug conjugates (ADCs), complex biologics, small molecules and gamma delta T cell therapies.

These therapies in development are investigational and have not been approved by any regulatory bodies for use in the investigational indications listed below.

Investigational therapyModalityInvestigational indicationPhase
Plus

Brentuximab vedotin*

ADC

Newly diagnosed Hodgkin lymphoma (EU)

Phase 3

Plus

Cabozantinib*

Small molecule

Metastatic castration-​resistant prostate cancer (JP)

Phase 3

Plus

Dazostinag (TAK-676)

Small molecule

Solid tumors

Phase 1/2

Plus

Mirvetuximab soravtansine-gynx (TAK-853)

ADC

Folate receptor alpha (FRα)-positive ovarian cancer (JP)

Phase 1/2

Plus

TAK-012

Gamma delta T cell therapy

Acute myeloid leukemia

Phase 1/2a

Plus

TAK-186

Complex Biologic

Solid tumors

Phase 1/2

Plus

TAK-280

Complex Biologic

Solid tumors

Phase 1/2

Plus

TAK-500

ADC

Solid tumors

Phase 1/2

  • *Marketed products have received approval in one or more jurisdictions.

  • All programs have global development rights unless otherwise noted.

  • GL = global (USA, Europe, Japan, China) / EU = Europe / JP = Japan / CN = China / GEM = global emerging markets

Investors

To learn more about Oncology-specific Investor events and information, visit the Takeda Oncology Investor Relations page

Explore IR
Banner Image

Explore More

Card image

Science

Decades of leadership in Oncology with a diverse and robust pipeline.
Card image

Partnership Strategy

We believe the best way to achieve our aspiration to cure cancer is by working together.
Newsroom

Newsroom

Keep up on the latest Oncology news by visiting our newsroom.

All trademarks are the property of their respective owners.

©2024 Takeda Pharmaceuticals U.S.A., Inc.

All rights reserved.   01/23